December 27th, 2013
2013 In Review: Our Top 12 Posts
Harlan M. Krumholz, MD, SM and CardioExchange Editors, Staff
After an incredibly busy year we took a moment to reflect on our top stories. In no particular order, these are among the most viewed posts on CardioExchange over the past year. My personal favorite of the year was Victor Montori’s questioning of PRAMI. Take a look and let us know what was your favorite feature of the year. –Harlan Krumholz
Niacin Therapy in the Crossfire
- William E. Boden, lead investigator of the AIM-HIGH trial, and Harlan Krumholz debate the role of niacin.
Revisiting Novel Anticoagulants in Atrial Fibrillation
- Christian Thomas Ruff and Andrew E. Epstein answer questions about using these agents in patients with AF.
Renal Denervation: Delineating Its Uses, Misuses, and Possibilities
- Murray David Esler, Chief Investigator of Symplicity HTN-2, answers questions about renal denervation.
Persistent Chest Pain After Myopericarditis
- We asked five esteemed clinicians– James Fang, James de Lemos, Kamalendu Kanu Chatterjee,Thomas Ryan, and Rick Akira Nishimura– for their differing perspectives on a challenging condition.
The Mediterranean Diet in Clinical Practice: Three Experts Weigh In
- Walter Willett, Arthur Agatston, and Alice Lichtenstein comment on the influential PREDIMED study.
ACC.13: Is Cangrelor an Antiplatelet CHAMPION?
- Deepak Bhatt, lead author of the CHAMPION PHOENIX trial, answers questions from CardioExchange’s interventional cardiology editors, Rick Lange and David Hillis.
DIGging In: Three Reasons Why the Recent Digoxin Study Is Not Relevant to Readmission
- Harlan Krumholz digs in to a new analysis of an old study.
“Your Mortality Risk Is 11.827%”
- John Brush asks what exactly does an event’s numeric probability tell us?
Look Before Leaping to Conclusions About Bush’s Stent
- Ajay Kirtane writes about media overreaction to the Bush stent news.
Scrutinizing the PRAMI Trial of “Preventive Angioplasty”
- Victor Montori offers his analysis of the PRAMI trial.
The Benefits of Switching From Hydrochlorothiazide to Chlorthalidone: What’s Stopping Us?
- Medical student Nicholas Bergfeld raises an important but often overlooked question.
The TACT Investigators Respond to Questions
- The TACT investigators– Gervasio A. Lamas, Christine Goertz, Robin Boineau, Daniel Mark, Richard L. Nahin, and Kerry L. Lee– answered questions about their extremely controversial trial.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?